U.S. Markets close in 33 mins

FSD Pharma Inc. (HUGE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.7400-0.0600 (-3.33%)
As of 3:21PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.8000
Open1.8200
Bid1.7400 x 1000
Ask1.7500 x 900
Day's Range1.7200 - 1.8399
52 Week Range1.7200 - 14.0000
Volume133,549
Avg. Volume748,196
Market Cap33.808M
Beta (5Y Monthly)0.54
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • FSD Pharma Inc. Announces Closing of US$9.5 Million Registered Direct Offering
    Business Wire

    FSD Pharma Inc. Announces Closing of US$9.5 Million Registered Direct Offering

    FSD Pharma Inc. (Nasdaq: HUGE) ("FSD Pharma" or the "Company"), today announced the closing of previously announced definitive agreements with investors for the purchase and sale of 4,318,179 Class B Subordinate Voting Shares of the Company ("Shares") and warrants to purchase 3,454,543 Shares (collectively, the "Securities") at a purchase price of US$2.20 per Share in a registered direct offering. The warrants have an exercise price of US$2.60 per Share, are immediately exercisable and expire five years from the date of issuance.

  • FSD Pharma Inc. Announces US$9.5 Million Registered Direct Offering
    Business Wire

    FSD Pharma Inc. Announces US$9.5 Million Registered Direct Offering

    FSD Pharma Inc. (Nasdaq: HUGE) ("FSD Pharma" or the "Company"), today announced that it has entered into definitive agreements with investors for the purchase and sale of 4,318,179 Class B Subordinate Voting Shares of the Company ("Shares") and warrants to purchase 3,454,543 Shares (collectively, the "Securities") at a purchase price of US$2.20 per Share in a registered direct offering. The warrants will have an exercise price of US$2.60 per Share, will be immediately exercisable and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about October 20, 2020, subject to the satisfaction of customary closing conditions.

  • FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients
    Business Wire

    FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients

    FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) ("FSD Pharma" or the "Company") announced that the U.S. Food and Drug Administration ("FDA") has authorized the initiation of a Phase 2 study for the use of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus (the "FSD201 COVID-19 Trial"). The company is expected to start dosing patients in October 2020. We believe FSD201 may have the potential to address the over-exuberant inflammatory response characterized by COVID-19 infection that may lead to a cytokine storm and ultimately death.